Top Markets
#1 Seeker Seeker +18.80%
#2 EXOD EXOD +9.04%
#3 Wrapped Aave Ethereum WETH Wrapped Aave Ethereum WETH +7.47%
#4 Arowana Arowana +5.88%
#5 MetaDAO MetaDAO +4.67%
#6 Wrapped STX (Velar) Wrapped STX (Velar) +4.02%
#7 Mina Protocol Mina Protocol +3.88%
#8 Pons Pons +3.00%
#9 Solstice Solstice +2.88%
#10 Official Trump Official Trump +2.75%
Coin of the day
Seeker Seeker
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
GH Research PLC GH Research PLC

GH Research PLC

GHRS
Rang in Aktien #6594
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to... GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Aktienkurs
$28.53
Zuletzt synchronisiert: 2026-08-27
Marktkapitalisierung
$1.96B
Veränderung (1 Tag)
-1.65%
Veränderung (1 Jahr)
106.14%
Land
IE
Handel GH Research PLC (GHRS)

Kategorie

Healthcare
P/B-Verhältnis für GH Research PLC (GHRS)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von GH Research PLC beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für GH Research PLC von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH